CAMBRIDGE, Mass., June 10 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) invites the public to listen to their 2002 Annual
Meeting of Stockholders via webcast on Friday, June 14, 2002 at 10:00 am.
To access the live webcast, please go to Biogen's homepage at
http://www.biogen.com.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and worldwide sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, and from the worldwide sales by licensees of a number of products.
Biogen's research and development activities are focused on novel products to
treat inflammatory and autoimmune diseases, neurological diseases, cancer,
fibrosis and congestive heart failure. The Company maintains active clinical
research programs in protein therapeutics, small molecules, genomics and gene
therapy. For copies of press releases and additional information about the
Company, please consult Biogen's Homepage on the World Wide Web at
http://www.biogen.com.
Contact:
Rob Jacobson
Investor Relations Specialist
Biogen, Inc.
617/679-3710
rob_jacobson@biogen.com
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Rob Jacobson, Investor Relations Specialist
of Biogen, Inc., +1- 617-679-3710, rob_jacobson@biogen.com
|
